Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03855956 · ClinicalTrials.gov registry record · NA
Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis
A NA study of Early Cirrhosis, sponsored by Kaleido Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT03855956 is a NA study of Early Cirrhosis that has completed, run by Kaleido Biosciences. The registered enrollment target is 40 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT03855956, a NA study of Early Cirrhosis, has completed, sponsored by Kaleido Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This randomized, double-blind, controlled, clinical food study aims to explore KB174, a novel mixture of oligosaccharides, and maltodextrin, an easily digestible polysaccharide, on gut microbiome structure and function in subjects with well-compensated cirrhosis.
Conditions Studied
Interventions
- OTHER Maltodextrin
- OTHER KB174
Study Locations (4)
Florida
- Research Centers of America - Hollywood
- Advanced Pharma CR, LLC - Miami
- Marquez Clinical Site Partners, LLC Florida Premier Research Institute - Winter Park
Louisiana
- Delta Research Partners - Monroe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-02-27 |
| Est. Completion | 2019-10-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03855956
The ClinicalTrials.gov registry entry for NCT03855956 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaleido Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Maltodextrin is the first listed.
NCT03855956 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT03855956 about?
NCT03855956 is a clinical study titled "Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis". This randomized, double-blind, controlled, clinical food study aims to explore KB174, a novel mixture of oligosaccharides, and maltodextrin, an easily digestible polysaccharide, on gut microbiome structure and function in subjects with well-compensated cirrhosis.
What is the current status of trial NCT03855956?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2019-02-27. Estimated completion is 2019-10-01.
What conditions does trial NCT03855956 study?
This clinical trial studies the following conditions: Early Cirrhosis.
What interventions are being tested in trial NCT03855956?
The interventions under investigation include: Maltodextrin (OTHER), KB174 (OTHER).
Who is sponsoring clinical trial NCT03855956?
This trial is sponsored by Kaleido Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03855956 being conducted?
This trial has 4 study locations across Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.